I.N.M. Neuromed, Localit Camerelle, Pozzilli, Italy.
Epilepsia. 2011 Jul;52(7):1211-22. doi: 10.1111/j.1528-1167.2011.03082.x. Epub 2011 May 13.
Metabotropic glutamate (mGlu) receptors are positioned at synapses of the thalamocortical network that underlie the development of spike-and-wave discharges (SWDs) associated with absence epilepsy. The modulatory role of individual mGlu receptor subtypes on excitatory and inhibitory synaptic transmission in the cortico-thalamo-cortical circuitry makes subtype-selective mGlu receptor ligands potential candidates as novel antiabsence drugs. Some of these compounds are under clinical development for the treatment of numerous neurologic and psychiatric disorders, and might be soon available for clinical studies in patients with absence seizures refractory to conventional medications. Herein we review the growing evidence that links mGlu receptors to the pathophysiology of pathologic SWDs moving from the anatomic localization and function of distinct mGlu receptor subtypes in the cortico-thalamo-cortical network to in vivo studies in mouse and rat models of absence epilepsy.
代谢型谷氨酸(mGlu)受体位于丘脑皮质网络的突触处，该网络是与失神性癫痫相关的棘波和慢波放电( SWD )产生的基础。特定 mGlu 受体亚型对皮质-丘脑-皮质回路中兴奋性和抑制性突触传递的调节作用，使得亚型选择性 mGlu 受体配体成为新型抗失神药物的潜在候选药物。其中一些化合物正在进行临床开发，用于治疗多种神经和精神疾病，并且可能很快就可以用于对传统药物难治性失神发作的患者进行临床研究。本文综述了越来越多的证据，这些证据将 mGlu 受体与病理性 SWD 的病理生理学联系起来，从皮质-丘脑-皮质网络中不同 mGlu 受体亚型的解剖定位和功能，到失神性癫痫的小鼠和大鼠模型中的体内研究。
